X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (60388) 60388
Newspaper Article (1691) 1691
Newsletter (664) 664
Book Chapter (277) 277
Magazine Article (261) 261
Book / eBook (33) 33
Publication (22) 22
Trade Publication Article (22) 22
Book Review (15) 15
Dissertation (6) 6
Reference (6) 6
Web Resource (6) 6
Conference Proceeding (5) 5
Government Document (3) 3
Paper (3) 3
Streaming Video (2) 2
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (49320) 49320
female (28291) 28291
male (28232) 28232
middle aged (19289) 19289
hemorrhage (17424) 17424
aged (17300) 17300
adult (14517) 14517
treatment outcome (10626) 10626
risk factors (9820) 9820
hemorrhage - chemically induced (8002) 8002
surgery (7721) 7721
animals (7587) 7587
stroke (7361) 7361
aged, 80 and over (6557) 6557
clinical neurology (6493) 6493
retrospective studies (6178) 6178
anticoagulants - adverse effects (5539) 5539
hematology (5425) 5425
mortality (5199) 5199
management (5176) 5176
care and treatment (5001) 5001
therapy (4901) 4901
peripheral vascular disease (4840) 4840
time factors (4811) 4811
anticoagulants (4620) 4620
anticoagulants - therapeutic use (4599) 4599
hemorrhage - etiology (4405) 4405
risk (4298) 4298
adolescent (4276) 4276
medicine, general & internal (4229) 4229
prospective studies (4113) 4113
cardiac & cardiovascular systems (4048) 4048
patients (3957) 3957
drug therapy (3859) 3859
medicine & public health (3776) 3776
warfarin (3737) 3737
subarachnoid hemorrhage (3717) 3717
abridged index medicus (3659) 3659
hemorrhage - drug therapy (3626) 3626
analysis (3614) 3614
bleeding (3576) 3576
prevention (3554) 3554
research (3524) 3524
health aspects (3449) 3449
gastroenterology & hepatology (3426) 3426
neurosciences (3410) 3410
follow-up studies (3365) 3365
intracerebral hemorrhage (3319) 3319
pregnancy (3210) 3210
gastrointestinal hemorrhage - etiology (3130) 3130
anticoagulants - administration & dosage (3069) 3069
pharmacology & pharmacy (2957) 2957
risk assessment (2850) 2850
child (2783) 2783
brain (2781) 2781
hemorrhage - prevention & control (2769) 2769
aspirin (2731) 2731
rats (2724) 2724
drug therapy, combination (2705) 2705
neurology (2679) 2679
thrombosis (2662) 2662
recurrence (2650) 2650
platelet aggregation inhibitors - adverse effects (2620) 2620
diagnosis (2540) 2540
young adult (2497) 2497
prognosis (2433) 2433
complications (2427) 2427
administration, oral (2393) 2393
ischemia (2367) 2367
clinical trials (2346) 2346
hypertension (2329) 2329
incidence (2277) 2277
platelet aggregation inhibitors - therapeutic use (2230) 2230
acute disease (2221) 2221
medical research (2201) 2201
thromboembolism (2195) 2195
disease models, animal (2180) 2180
gastrointestinal hemorrhage - drug therapy (2165) 2165
dose-response relationship, drug (2152) 2152
atrial fibrillation - drug therapy (2150) 2150
fibrinolytic agents - therapeutic use (2146) 2146
complications and side effects (2143) 2143
atrial fibrillation (2124) 2124
safety (2091) 2091
medicine (2088) 2088
pediatrics (2031) 2031
tomography, x-ray computed (2021) 2021
warfarin - adverse effects (2005) 2005
fibrinolytic agents - adverse effects (1990) 1990
stroke - drug therapy (1979) 1979
usage (1925) 1925
disease (1907) 1907
internal medicine (1886) 1886
infant, newborn (1855) 1855
randomized controlled trials as topic (1833) 1833
stroke - prevention & control (1822) 1822
studies (1818) 1818
double-blind method (1811) 1811
recombinant proteins - therapeutic use (1788) 1788
oncology (1756) 1756
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (58407) 58407
German (1478) 1478
French (1120) 1120
Russian (757) 757
Spanish (679) 679
Japanese (646) 646
Italian (334) 334
Chinese (275) 275
Polish (146) 146
Portuguese (119) 119
Danish (97) 97
Czech (87) 87
Dutch (86) 86
Hungarian (67) 67
Swedish (61) 61
Bulgarian (58) 58
Norwegian (44) 44
Ukrainian (35) 35
Romanian (34) 34
Serbian (29) 29
Korean (28) 28
Turkish (28) 28
Hebrew (22) 22
Croatian (17) 17
Finnish (11) 11
Slovak (9) 9
Lithuanian (8) 8
Arabic (3) 3
Bosnian (3) 3
Icelandic (2) 2
Persian (2) 2
Armenian (1) 1
Greek (1) 1
Latvian (1) 1
Slovenian (1) 1
Thai (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2015, Volume 313, Issue 11, pp. 1113 - 1121
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2019, Volume 321, Issue 13, pp. 1261 - 1274
.... DESIGN, SETTING, AND PARTICIPANTS: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation trial is an investigator-initiated, open-label, multicenter, randomized trial involving 126 centers in 10 countries... 
MEDICINE, GENERAL & INTERNAL | ACC/AHA/ESC 2006 GUIDELINES | WRITING COMMITTEE | EXPERT CONSENSUS STATEMENT | TASK-FORCE | AMERICAN-COLLEGE | HEART RHYTHM ASSOCIATION | SURGICAL ABLATION | WORLDWIDE SURVEY | EUROPEAN-SOCIETY | RADIOFREQUENCY ABLATION | Recurrence | Stroke - prevention & control | Atrial Fibrillation - drug therapy | Humans | Middle Aged | Risk Factors | Atrial Fibrillation - complications | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Male | Hemorrhage - prevention & control | Anti-Arrhythmia Agents - therapeutic use | Atrial Fibrillation - surgery | Stroke - etiology | Anti-Arrhythmia Agents - adverse effects | Atrial Fibrillation - mortality | Heart Arrest - prevention & control | Hemorrhage - etiology | Intention to Treat Analysis | Heart Arrest - etiology | Female | Registries | Aged | Catheter Ablation - adverse effects | Care and treatment | Dosage and administration | Comparative analysis | Atrial fibrillation | Anti-arrhythmia drugs | Heart | Cardiac arrhythmia | Stroke | Mortality | Medical instruments | Health risks | Clinical trials | Rhythm | Drug development | Risk analysis | Ablation | Patients | Bleeding | Catheters | Crossovers | Risk factors | Chemotherapy | Fibrillation | Death | Drug therapy | Cardiovascular diseases | Online First | Research | Comments | Original Investigation
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
...: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines... 
COMPUTERIZED DECISION-SUPPORT | INTENSITY WARFARIN THERAPY | DEFINITE ANTIPHOSPHOLIPID SYNDROME | RESPIRATORY SYSTEM | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | DEEP-VEIN THROMBOSIS | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | ACUTE VENOUS THROMBOEMBOLISM | ORAL VITAMIN-K | CRITICAL CARE MEDICINE | United States | Humans | Decision Support Systems, Clinical | Heparin - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Heparin - adverse effects | Heparin - pharmacokinetics | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Drug Interactions | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Thrombosis - prevention & control | Patient Education as Topic | Polysaccharides - therapeutic use | Drug Administration Schedule | Administration, Oral | Hemorrhage - therapy | Polysaccharides - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | International Normalized Ratio | Thrombosis - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Self Care | Polysaccharides - pharmacokinetics | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2019, Volume 321, Issue 24, pp. 2414 - 2427
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2015, Volume 65, Issue 8, pp. 777 - 786
Background The currently recommended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent... 
double antiplatelet duration | percutaneous coronary angioplasty | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | THROMBOSIS | BARE-METAL STENTS | FOLLOW-UP | RISK | PERCUTANEOUS CORONARY INTERVENTION | IMPACT | POOLED ANALYSIS | CLINICAL-OUTCOMES | PLATELET REACTIVITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Postoperative Complications - prevention & control | Male | Hemorrhage - prevention & control | Aspirin - administration & dosage | Drug-Eluting Stents - adverse effects | Middle East | Early Termination of Clinical Trials | Coronary Restenosis - diagnosis | Coronary Artery Disease - physiopathology | Time Factors | Aspirin - adverse effects | Percutaneous Coronary Intervention - methods | Hemorrhage - etiology | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Everolimus | Coronary Restenosis - etiology | Platelet Aggregation Inhibitors - adverse effects | Coronary Vessels - pathology | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Europe | Coronary Restenosis - prevention & control | Treatment Outcome | Coronary Artery Disease - mortality | Postoperative Complications - diagnosis | Ticlopidine - analogs & derivatives | Coronary Artery Disease - therapy | Coronary Artery Disease - diagnosis | Coronary Vessels - surgery | Aged | Percutaneous Coronary Intervention - adverse effects | Aspirin
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
.... Methods: We used the methods described in the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e576S - e600S
Background: Antithrombotic therapy in valvular disease is important to mitigate thromboembolism, but the hemorrhagic risk imposed must be considered. Methods... 
PROSTHETIC VALVE | LOW-DOSE ASPIRIN | MITRAL ANNULAR CALCIFICATION | PATENT FORAMEN OVALE | RESPIRATORY SYSTEM | MOLECULAR-WEIGHT HEPARIN | ORAL ANTICOAGULANT-THERAPY | CEREBRAL ISCHEMIC EVENTS | AORTIC-VALVE-REPLACEMENT | SPONTANEOUS ECHO-CONTRAST | LEFT ATRIAL THROMBUS | CRITICAL CARE MEDICINE | Heart Valve Diseases - blood | Mitral Valve | Thrombosis - complications | Ductus Arteriosus, Patent - drug therapy | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Stroke - complications | Hemorrhage - prevention & control | Rheumatic Heart Disease - blood | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Ductus Arteriosus, Patent - blood | Thromboembolism - prevention & control | Aspirin - adverse effects | Heart Valve Diseases - complications | Fibrinolytic Agents - therapeutic use | Rheumatic Heart Disease - drug therapy | Rheumatic Heart Disease - complications | Aspirin - therapeutic use | Thromboembolism - drug therapy | Postoperative Complications - drug therapy | Thrombosis - blood | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Catheterization | Heart Atria | Heart Valve Prosthesis | Risk Factors | Ductus Arteriosus, Patent - complications | Combined Modality Therapy | Evidence-Based Medicine | Stroke - blood | Thromboembolism - blood | Heart Valve Diseases - drug therapy | Thrombosis - drug therapy | Hemorrhage - chemically induced | Thrombolytic Therapy - adverse effects | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e737S - e801S
Background: Neonates and children differ from adults in physiology, pharmacologic responses to drugs, epidemiology, and long-term consequences of thrombosis... 
INFERIOR VENA-CAVA | TISSUE-PLASMINOGEN-ACTIVATOR | ARTERIAL ISCHEMIC-STROKE | RESPIRATORY SYSTEM | CEREBRAL SINOVENOUS THROMBOSIS | ACUTE LYMPHOBLASTIC-LEUKEMIA | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | SICKLE-CELL-DISEASE | HOMOZYGOUS PROTEIN-C | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Humans | Upper Extremity Deep Vein Thrombosis - blood | Child, Preschool | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Upper Extremity Deep Vein Thrombosis - prevention & control | Hemorrhage - prevention & control | Secondary Prevention | Heparin - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Cardiac Catheterization | Vitamin K - antagonists & inhibitors | Societies, Medical | Platelet Aggregation Inhibitors - administration & dosage | Renal Veins | Thrombosis - blood | Thrombosis - prevention & control | Child | Infant, Newborn | Platelet Aggregation Inhibitors - adverse effects | Upper Extremity Deep Vein Thrombosis - drug therapy | Drug Administration Schedule | Risk Factors | Cooperative Behavior | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Interdisciplinary Communication | Thrombosis - etiology | Blood Coagulation Tests | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e419S - e496S
... (PE), we recommend initial parenteral anticoagulant therapy (Grade 1B) or anticoagulation with rivaroxaban... 
RIGHT-VENTRICULAR DYSFUNCTION | RECURRENT VENOUS THROMBOEMBOLISM | TISSUE-PLASMINOGEN-ACTIVATOR | RESPIRATORY SYSTEM | ACUTE PULMONARY-EMBOLISM | MOLECULAR-WEIGHT HEPARIN | VENA-CAVA FILTER | ORAL ANTICOAGULANT-THERAPY | INTRAVENOUS UNFRACTIONATED HEPARIN | LONG-TERM TREATMENT | DEEP-VEIN-THROMBOSIS | CRITICAL CARE MEDICINE | Venous Thrombosis - diagnosis | Pulmonary Embolism - prevention & control | United States | Humans | Venous Thrombosis - blood | Heparin, Low-Molecular-Weight - adverse effects | Hemorrhage - prevention & control | Long-Term Care | Heparin, Low-Molecular-Weight - therapeutic use | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - prevention & control | Polysaccharides - therapeutic use | Drug Administration Schedule | Venous Thrombosis - drug therapy | Administration, Oral | Risk Factors | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Pulmonary Embolism - blood | International Normalized Ratio | Diagnostic Imaging | Pulmonary Embolism - diagnosis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 01/2012, Volume 125, Issue 3, pp. 505 - 513
Journal Article